Mogamulizumab
| 證據等級: L5 | 預測適應症: 7 個 |
目錄
- Mogamulizumab
- Mogamulizumab: From Cutaneous T-Cell Lymphoma to Prostatic Urethra Urothelial Carcinoma
Mogamulizumab: From Cutaneous T-Cell Lymphoma to Prostatic Urethra Urothelial Carcinoma
One-Sentence Summary
Mogamulizumab is a humanized anti-CCR4 monoclonal antibody historically associated with cutaneous T-cell lymphoma (CTCL)/Sézary syndrome (per the evidence pack's mechanistic notes; not present in the structured indication record). The TxGNN model predicts it may be effective for prostatic urethra urothelial carcinoma, but 0 clinical trials and 0 publications currently support this direction — this is a pure computational prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Cutaneous T-cell lymphoma (CTCL) / Sézary syndrome — referenced only in the evidence-pack rationale text; not captured in the structured original_indications field |
| Predicted New Indication | Prostatic urethra urothelial carcinoma |
| TxGNN Prediction Score | 99.44% (rank 5955) |
| Evidence Level | L5 |
| Norway Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Structured mechanism-of-action data is not available for this drug (original_moa: [Data Gap]). However, the repurposing rationale attached to each candidate consistently describes mogamulizumab as a humanized anti-CCR4 monoclonal antibody that depletes CCR4-positive tumor-infiltrating regulatory T cells (Tregs) via antibody-dependent cellular cytotoxicity (ADCC), thereby relieving tumor-mediated immune suppression.
The predicted new indications — urothelial carcinomas of the prostatic urethra, renal pelvis, and bladder, plus several rare tumors (HHV8-related tumors, ectomesenchymoma, malignant granular cell skin tumor) — are linked to the original mechanism only through a general biological hypothesis: many solid tumors show CCR4+ Treg infiltration, and depleting these cells could theoretically restore anti-tumor immunity. None of the seven candidates have specific biomarker data, preclinical models, or clinical experience cited in this evidence pack to confirm CCR4/Treg involvement in these specific tumor types.
In short, this is a mechanistically plausible but entirely unvalidated extrapolation. The TxGNN score reflects network-based similarity in the knowledge graph, not experimental or clinical evidence.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Norway Market Information
Mogamulizumab currently holds no market authorizations in Norway (total_licenses: 0, market_status: 未上市). No product listings, dosage forms, or approved indication text are available in the evidence pack.
Cytotoxicity
Mogamulizumab is an antineoplastic biologic (anti-CCR4 monoclonal antibody, immunotherapy class); the section below is included accordingly.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Immunotherapy (anti-CCR4 monoclonal antibody; Treg-depleting mechanism, not a conventional cytotoxic agent) |
| Myelosuppression Risk | Not characterized in this evidence pack. Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Low (typical for antibody-based immunotherapies, which generally carry minimal direct emetogenic potential) |
| Monitoring Items | CBC, skin/mucocutaneous examination, infusion-reaction monitoring, and surveillance for immune-related adverse events (liver function, thyroid function, GI symptoms) — consistent with monoclonal antibody immunotherapy class |
| Handling Protection | No cytotoxic hazardous-drug data provided; confirm handling requirements against institutional biologics/monoclonal antibody infusion protocols |
Safety Considerations
Please refer to the package insert for safety information.
Note: This is a Blocking data gap (DG001 — TFDA/label warnings and contraindications unavailable), which by itself is sufficient to prevent progression past initial safety screening (S1).
Conclusion and Next Steps
Decision: Hold
Rationale: All seven predicted indications sit at evidence level L5 (model prediction only, no trials or literature), the drug is not marketed in Norway, and a Blocking safety data gap (TFDA/label warnings and contraindications) prevents any safety pre-screening. There is currently no basis to advance beyond the hypothesis stage.
To proceed, the following is needed:
- Resolve DG001: obtain TFDA/regulatory label data (warnings, contraindications, DDI)
- Resolve DG002: confirm mechanism of action via DrugBank API (beyond the rationale-text description)
- Confirm the drug's actual original approved indication(s) in structured form
- Targeted literature/trial search for CCR4 expression or Treg infiltration in urothelial carcinoma and the other candidate tumor types
- If any signal emerges, prioritize preclinical/biomarker studies before considering clinical evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.